Mantle Cell Lymphoma Clinical Trials

48 studies are recruiting for mantle cell lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

   This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth …

   Stage

   Phase 2

   Ages

   0 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   Fred Hutchinson Cancer Center

   See if you can join NCT04195633 on ClinicalTrials.gov

2. Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

   To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05529069 on ClinicalTrials.gov

3. Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

   To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06263491 on ClinicalTrials.gov

4. Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

   Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive…

   Stage

   Phase 1

   Ages

   12 to 70

   Site

   New York Medical Center, Valhalla, New York

   Run by

   New York Medical College

   See if you can join NCT04491370 on ClinicalTrials.gov

5. SynKIR-310 for Relapsed/Refractory B-NHL

   This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver, Colorado

   Locations

   5 in total

   Run by

   Verismo Therapeutics

   See if you can join NCT06544265 on ClinicalTrials.gov

6. Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

   This phase II trial tests how well nemtabrutinib works with rituximab for the treatment of patients with mantle cell lymphoma. Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such a…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   2 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06572618 on ClinicalTrials.gov

7. Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

   This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.

   Stage

   Not phased

   Ages

   Any age

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT06151730 on ClinicalTrials.gov

8. Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

   This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell transplant in treating patients with high grade B-cell non-Hodgkin lymphoma. …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT05432635 on ClinicalTrials.gov

9. BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

   This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubrutinib and Rituximab with or without Sonrotoclax in participants with Mantle Cell Lymphoma (MCL). T…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Beth Israel Deaconess Medical Center, Boston, Massachusetts

   Locations

   7 in total

   Run by

   Christine Ryan

   See if you can join NCT06854003 on ClinicalTrials.gov

10. Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

    This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Duke Univerisity, Durham, North Carolina

    Locations

    4 in total

    Run by

    Newave Pharmaceutical Inc

    See if you can join NCT04775745 on ClinicalTrials.gov

11. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner Health - MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    36 in total

    Run by

    Schrödinger, Inc.

    See if you can join NCT05544019 on ClinicalTrials.gov

12. CONFIRM: Magnetic Resonance Guided Radiation Therapy

    This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Brigham & Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT04368702 on ClinicalTrials.gov

13. Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

    This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of cancer cells by blo…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT04883437 on ClinicalTrials.gov

14. Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

    This phase IB/II trial tests the safety, side effects and effectiveness of glofitamab plus ibrutinib with obinutuzumab for the treatment of patients with mantle cell lymphoma (MCL). Glofitamab is in a class of medications called bispecific monoclonal antibodies. It works by killing cancer cells. A …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT06357676 on ClinicalTrials.gov

15. Avo In R/R And Previously Untreated MCL

    This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib * Venetoclax * Obinu…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Chicago Medical Center, Chicago, Illinois

    Locations

    3 in total

    Run by

    Austin I Kim

    See if you can join NCT04855695 on ClinicalTrials.gov

16. Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

    This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the kappa light chain antibody on cancer cells. For th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT04223765 on ClinicalTrials.gov

17. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

    A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    St Vincent's Hospital, Darlinghurst, New South Wales

    Locations

    16 in total

    Run by

    OncoNano Medicine, Inc.

    See if you can join NCT06022029 on ClinicalTrials.gov

18. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

    This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC Irvine Health, Orange, California

    Locations

    13 in total

    Run by

    Carna Biosciences, Inc.

    See if you can join NCT05602363 on ClinicalTrials.gov

19. A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

    This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Kansas, Westwood, Kansas

    Locations

    7 in total

    Run by

    CRISPR Therapeutics AG

    See if you can join NCT05643742 on ClinicalTrials.gov

20. Long-term Follow-up Study of Patients Receiving CAR-T Cells

    This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refracto…

    Stage

    Not phased

    Ages

    18 to 80

    Site

    Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT03375619 on ClinicalTrials.gov

21. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Birmingham, Alabama

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

22. Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

    This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

    Stage

    Phase 2

    Ages

    18 to 79

    Site

    AHN Cancer Institute - West Penn Hospital, Pittsburgh, Pennsylvania

    Run by

    John Lister

    See if you can join NCT05281809 on ClinicalTrials.gov

23. Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

    In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ p…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Stanford Cancer Center, Palo Alto, California

    Run by

    Adaptive Biotechnologies

    See if you can join NCT05255354 on ClinicalTrials.gov